When adjusted for treatment duration, the incidence of TE ascites was no higher in patients who received ramucirumab than in those who received placebo. Ramucirumab was well tolerated and provided a survival benefit irrespective of the development of TE ascites.
Andrew X. Zhu, Masafumi Ikeda, Peter R. Galle, Tatsuya Yamashita, Josep M. Llovet, Kun Liang, Chunxiao Wang, Sachi Sakaguchi, Paolo Abada, Ryan C. Widau, Masatoshi Kudo
Josep M. Llovet, Amit G. Singal, Augusto Villanueva, Richard S. Finn, Masatoshi Kudo, Peter R. Galle, Chunxiao Wang, Ryan C. Widau, Elena González Gugel, Andrew X. Zhu
Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo
Josep M. Llovet, Amit G. Singal, Augusto Villanueva, Richard S. Finn, Masatoshi Kudo, Peter R. Galle, Masafumi Ikeda, Sophie Callies, Louise M. McGrath, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Elena Gonzalez-Gugel, Andrew X. Zhu
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu
Discussion(0)
No comments yet. Be the first to comment.